SARS-CoV-2 RNA and antibody detection in breast milk from a prospective multicentre study in Spain

Christine Bäuerl, Walter Randazzo, Gloria Sánchez, Marta Selma-Royo, Elia García Verdevio, Laura Martínez, Anna Parra-Llorca, Carles Lerín, Victoria Fumadó, Francesca Crovetto, Fatima Crispi, Francisco J Pérez-Cano, Gerardo Rodríguez, Gemma Ruiz-Redondo, Cristina Campoy, Cecilia Martínez-Costa, Maria Carmen Collado on behalf of MilkCORONA study team

ABSTRACT

Objectives To develop and validate a specific protocol for SARS-CoV-2 detection in breast milk matrix and to determine the impact of maternal SARS-CoV-2 infection on the presence, concentration and persistence of specific SARS-CoV-2 antibodies.

Design and patients This is a prospective, multicentre longitudinal study (April–December 2020) in 60 mothers with SARS-CoV-2 infection and/or who have recovered from COVID-19. A control group of 13 women before the pandemic were also included.

Setting Seven health centres from different provinces in Spain.

Main outcome measures Presence of SARS-CoV-2 RNA in breast milk, targeting the N1 region of the nucleocapsid gene and the envelope (E) gene; presence and levels of SARS-CoV-2-specific immunoglobulins (Igs)—IgA, IgG and IgM—in breast milk samples from patients with COVID-19.

Results All breast milk samples showed negative results for presence of SARS-CoV-2 RNA. We observed high intraindividual and interindividual variability in the antibody response to the receptor-binding domain of the SARS-CoV-2 spike protein for each of the three isotypes IgA, IgM and IgG. Main Protease (MPro) domain antibodies were also detected in milk. 82.9% (58 of 70) of milk samples were positive for at least one of the three antibody isotypes, with 52.9% of these positive for all three Igls. Positivity rate for IgA was relatively stable over time (65.2%–87.5%), whereas it raised continuously for IgG (from 47.8% for the first 10 days to 87.5% from day 41 up to day 206 post-PCR confirmation).

Conclusions Our study confirms the safety of breast feeding and highlights the relevance of virus-specific SARS-CoV-2 antibody transfer. This study provides crucial data to support official breastfeeding recommendations based on scientific evidence.

Trial registration number NCT04768244.

INTRODUCTION

Breast feeding is considered the gold standard for infant feeding and is of crucial importance in influencing both infant growth and development. Epidemiological studies have demonstrated that breast feeding decreases risk of infections in infants.1–4 Due to its beneficial effects, international organisations including the WHO recommend exclusive breast feeding for the first 6 months of life, and continuing breast feeding while complementary foods are introduced until 2 years of age or beyond.5 The COVID-19 global pandemic caused by SARS-CoV-2 has increased concerns about potential mother-to-infant transmission, including via breast feeding. While some studies reported the presence of SARS-CoV-2 in breast milk,6 7 although its potential for infection is unclear,8 other studies found no presence of the virus.9 10 11 In general, these studies showed several limitations, with the most relevant being the lack of targeted and validated protocols for viral detection in milk matrix. Furthermore, a strong antibody response is induced after maternal SARS-CoV-2 infection, with higher presence of neutralising secretory IgA in breast milk.7 12 13 However, several questions remain unanswered, including a specific and reliable method to detect SARS-CoV-2 in human milk, the extent of
the response, the persistence of maternal antibodies in milk and their potential protective role in infants. Under this scenario, our main objectives were (1) to provide a specific and reliable detection method for SARS-CoV-2 in breast milk; and (2) to determine the levels of reactive IgA, IgG and IgM antibodies against structural and non-structural SARS-CoV-2 proteins in breast milk collected during the COVID-19 pandemic.

MATERIALS AND METHODS

Study population
This is a prospective, observational, longitudinal and multicentre study in mother–infant pairs with confirmed SARS-CoV-2 infection. Participants were recruited from seven health centres from different provinces in Spain (Valencia, Barcelona, Granada and Zaragoza). The recruitment period was from April to December 2020. Participants were pregnant women intending to breast feed and nursing women with positive PCR for SARS-CoV-2 on nasopharyngeal swabs or presence of SARS-CoV-2 antibodies in serum determined in hospitals. Women were excluded when COVID-19 symptomatology required specific treatment and/or hospitalisation in intensive care units. Exclusion criteria included women unable to breast feed due to severe symptomatology that required intensive care unit and/or mother’s need for drugs with potential adverse effects on the infant and/or impossibility to obtain milk. All participants received oral and written information about the study and written consent was obtained. Extended details on the control group are described in online supplemental text S1.

Breast milk collection and processing
Breast milk was collected following a standardised protocol described elsewhere.\textsuperscript{14} Details on collection, sampling and storage are described in online supplemental text S1. Whole milk was used for SARS-CoV-2 RNA detection and whey milk was used for antibody determination. Further details are provided in online supplemental text S1.

Validation of SARS-CoV-2 RNA extraction, detection and quantification in breast milk samples
A manual column-based commercial kit (referred to as MN) and an automated assisted method based on magnetic beads (referred to as Max) were adapted following previous recommendations\textsuperscript{15} and were compared to assess their sensitivity in detecting viral particles in breast milk. Details related to RNA extraction procedures, viral recoveries with different virus and limits of detection (LoD\textsubscript{95%} and LoD\textsubscript{50%}) are provided in online supplemental text S1.

Breast milk SARS-CoV-2-specific antibody detection
Levels of antibodies directed to structural (receptor-binding domain (RBD) of the SARS-CoV-2 spike protein) and non-structural (the main protease MPro or 3C-like protease (3CLpro)) viral proteins were analysed (online supplemental text S1). RBD-specific antibodies were determined by ELISA as previously described.\textsuperscript{16,17} MPro-reactive antibodies were quantified using a commercial ELISA kit (ImmunoStep, Salamanca, Spain).

RESULTS

Study population characteristics
Maternal demographic and clinical characteristics of women from the COVID-19 pandemic period group (n=60) and the prepandemic group (n=13) are described in Table 1. Among the 60 mothers, 52 were diagnosed with SARS-CoV-2 PCR test on nasopharyngeal swabs while 8 were seropositive (IgG-positive). Most PCR tests (38 of 52, 73.1%) were performed as part of routine surveillance before labour (online supplemental text S2,

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Characteristics of the volunteers included in the study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal characteristics</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>34.8±4.6*</td>
</tr>
<tr>
<td>Gestational age (weeks)†</td>
<td>39.2 (38.1–40.6)‡§</td>
</tr>
<tr>
<td>Delivery mode, n (%)¶</td>
<td></td>
</tr>
<tr>
<td>Vaginal</td>
<td>42 (76.4)</td>
</tr>
<tr>
<td>Caesarean section</td>
<td>13 (23.6)</td>
</tr>
<tr>
<td>Infant characteristics</td>
<td></td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>3247±519†</td>
</tr>
<tr>
<td>Birth length (cm)</td>
<td>49.8±2.41†</td>
</tr>
<tr>
<td>Breastfeeding status§§, n (%)</td>
<td></td>
</tr>
<tr>
<td>Exclusive</td>
<td>35 (66.0)</td>
</tr>
<tr>
<td>Mixed feeding</td>
<td>18 (34.0)</td>
</tr>
<tr>
<td>Gender¶¶, n (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>24 (44.4)</td>
</tr>
<tr>
<td>Female</td>
<td>30 (55.6)</td>
</tr>
</tbody>
</table>

*Missing data from 4 individuals.
†Unpaired t-test.
‡Values are given as median and 25th and 75th percentile.
§Missing data from 10 individuals.
¶Missing data from 5 individuals.
**Fisher’s exact test (two-sided).
††Missing data from 8 individuals.
‡‡Missing data from 14 individuals.
§§Missing data from 7 individuals.
¶¶Missing data from 6 individuals.
Validation of SARS-CoV-2 RNA extraction and detection methods in breast milk

Breast milk SARS-CoV-2 viral RNA detection was optimised with Porcine Epidemic Diarrhoea Virus (PEDV) strain CV777 and Mengovirus (MgV) vMC0 strain recoveries, and limits of detection (LoD_{MgV} and LoD_{PEDV}) from spiked prepreparative breast milk samples using manual (MN) and an automated (Max) extraction method were tested (online supplemental text S2). These results suggested comparable analytical performance of both extraction methods for enveloped viruses; thus, the Max extraction method was further characterised using gamma inactivated SARS-CoV-2 and human coronavirus (HCoV) 229E (ATCC VR740) (online supplemental figure S1), along with PEDV and MgV, as the method intended to be used for screening breast milk samples from women with COVID-19. LoD_{PEDV} values were as low as 36 gc/100 μL, 209 gc/100 μL, 13 gc/100 μL and 7 gc/100 μL, and LoD_{MgV} values were 8 gc/100 μL, 48 gc/100 μL, 3 gc/100 μL and 2 gc/100 μL, for SARS-CoV-2, HCoV 229E, PEDV and MgV, respectively (online supplemental figure S2). Based on these analytical results, the Max method was selected to screen the 72 breast milk samples for presence of SARS-CoV-2 RNA. Targeting the N1 and E regions, all samples resulted negative for presence of SARS-CoV-2 RNA. The RP gene used as quality control excluded false negative results (Cq=27.98±3.04). No remaining volume was available from 2 out of the 72 samples for the following analyses.

SARS-CoV-2 reactive antibodies in breast milk

We tested the reactivity of breast milk IgA, IgM and IgG antibodies to the RBD of the spike glycoprotein. Preparademic milk samples (n=13) served as controls and to determine positive cut-off values (online supplemental figure S3). Strong reactivity was found for IgA, IgM and IgG in milk samples from COVID-19 infected/recovered women, and low levels of non-specific binding were observed in the prepreparative samples (online supplemental figure S4a-c). When applying positive cut-off levels, 84.5% (49 of 58) of the milk samples were positive for the RBD antigen for at least one of the three antibody classes (online supplemental figure S4d). When analysing the 70 collected samples, 58 (82.9%) were positive for at least one of the three antibody classes (IgA, IgM or IgG). Thirty-seven milk samples (52.9%) were positive for all three immunoglobulins (Igs), whereas 12 samples (17.1%) did not show reactivity to RBD for any of the three antibody classes (IgA, IgM or IgG). Thirty-seven milk samples (52.9%) were positive for all three immunoglobulins (Igs), whereas 12 samples (17.1%) did not show reactivity to RBD for any of the three antibody classes (IgA, IgM or IgG). Thirty-seven milk samples (52.9%) were positive for all three immunoglobulins (Igs), whereas 12 samples (17.1%) did not show reactivity to RBD for any of the three antibody classes (IgA, IgM or IgG).

Antibody response was analysed as a function of time from diagnosis with PCR test (online supplemental figure S6). The positivity rate for IgA was relatively stable over time (65.2%–87.5%). Most positive samples for IgM were detected when collected at 11–20 days after PCR confirmation (83.3%), and then the levels consistently declined to 62.5%. IgG positivity rate continuously raised from 47.8% to 87.5% from day 41 up to day 206 post-PCR confirmation. RBD-specific IgA response in symptomatic COVID-19 cases tended to be higher than in the asymptomatic group, although differences did not reach significance and no changes were detected in virus-specific IgM and IgG (online supplemental figure S7).

We compared endpoint titres of positive samples between the different antibody isotypes and observed that the magnitude of the response was similar for all three Igs (online supplemental figure S8). Furthermore, all three Igs significantly correlated with each other, particularly IgA and IgM (r=0.7812, p<0.0001), but also IgA and IgG (r=0.6100, p<0.0001) and IgG and IgM (r=0.5708, p=0.0001).

A positive correlation (r=0.5527, p=0.0001) was also observed between the total IgA levels and the SARS-CoV-2-specific antibody response (online supplemental figure S9a). In fact, the total IgA levels were significantly higher in the COVID-19 group compared with the preparademic controls (online supplemental figure S9b) and could be part of the response to infection. In a subset of longitudinal milk samples collected within the first 20 days after birth, we observed a generalised decrease in IgA and endpoint titres for RBD except in one mother, which exhibited low but rising antibody titres in breast milk (online supplemental figure S10). Generally, total IgA concentrations correlated negatively with lactation stage (r=−0.3357, p=0.0045), similar to RBD-specific IgA (r=−0.3088, p=0.0093) and IgM (r=−0.4334, p=0.0002), while the RBD-specific IgG response was independent of lactation stage. Furthermore, there was high interindividual and intraindividual variability in the antibody response to the virus for each of the three isotypes (online supplemental figure S11). In most of the samples, lactation stage and post-PCR detection coincided in a narrow time period; in fact, for 40 of the positive tested samples in online supplemental figure S11a, the difference between PCR detection and birth was not more than 5 days. Seven out of the eight milk samples from seropositive women showed positive antibody responses for all three antibody classes, except one sample that tested negative for IgM (online supplemental figure S11b). The remaining sample tested negative for all three isotypes and was from a mother diagnosed with SARS-CoV-2 infection by serological testing 226 days prior to sample collection for our study.

DISCUSSION

During the current COVID-19 pandemic, science has primarily focused on providing solutions and treatments against SARS-CoV-2 infection to reduce mortality. However, specific vulnerable populations including pregnant and lactating mothers as well as infants have not been widely considered, resulting in a big gap in knowledge on maternal-infant health regarding COVID-19.

Breast feeding is considered the most relevant postnatal link between mothers and infants. However, the lack of understanding of SARS-CoV-2 vertical transmission has considerably reduced breastfeeding practice. Even mothers with SARS-CoV-2 infection were recommended to temporarily separate from their infants.

Being a rapid and sensitive technique, RNA detection by reverse transcription quantitative PCR (RT-qPCR) is the gold standard for both clinical diagnosis and viral food contamination. However, milk components might affect nucleic acid isolation and quantification, as demonstrated by the variable recovery of contaminating microorganisms and the occurrence of (partial/total) inhibitory effect during amplification, which may cause underestimated and false negative results, as we...

Original research

Table S1). Longitudinal samples from 12 women were available (two time points at <7 days and 15 days after delivery, approximately). Of the women, 38 (63.3%) were asymptomatic, and the rest reported mild COVID-19 symptoms (pain, fatigue or headache, among others). No other effects or medical problems were reported. All neonates were negative for SARS-CoV-2 and in good health.
have also observed. Thus, it is of primary importance to include appropriate quality controls for extraction, detection and quantification of molecular targets while defining the analytical performance of the overall workflow.26 In study, whole milk was used to test for viral RNA presence. LoD95% and LoD50% for gamma inactivated SARS-CoV-2 resulted in values as low as 36 gc/100 μL and 8 gc/100 μL, respectively. These data are in line with the detection limit suggested by Chambers and colleagues,25 where samples with >25 gc/100 μL of SARS-CoV-2 RNA would be considered positive although a higher limit of ca. 10-14 gc/100 μL was informed elsewhere.6

Available data show that around 2%-6% of milk samples would harbour viral RNA. A recent systematic review (n=37 articles with 68 lactating mothers with COVID-19) showed that SARS-CoV-2 RNA was detected in nine of the samples (9 of 68, 13.2%).28 Another systematic review reported that SARS-CoV-2 RNA detection in breast milk was 2.16%.29

The biggest study to date included 110 women in the USA (n=65 testing positive for SARS-CoV-2) and showed that SARS-CoV-2 RNA was present in 6% of the milk samples; however, no infectious viral particles could be isolated by cell culture.8 By using SARS-CoV-2, SARS-CoV-2 surrogates and a non-enveloped viral model (MgV), we define the analytical performance (eg, recovery and LoD) of a specific protocol able to efficiently isolate and detect SARS-CoV-2 RNA in breast milk. We further validate the protocol using appropriate quality controls in whole breast milk.

In our study, we have not detected SARS-CoV-2 RNA in any of the breast milk samples, contributing to the evidence that there is no vertical transmission during breast feeding.9 There are still many open questions: when are SARS-CoV-2 antibodies produced after maternal infection, when can they be detected in breast milk, and how long do they persist? While different studies reported the presence of SARS-CoV-2-specific IgA antibodies,7 12 13 30 limited information is available on IgG and IgM. Our results showed the presence of anti-SARS-CoV-2 antibodies in milk, primarily IgA but also IgG and IgM targeting RBD. High intra-individual and inter-individual variability was observed in antibody presence, and significant differences for all three antibody classes were identified when compared with the prepandemic samples.18 We did not detect time-dependent quantitative differences in endpoint titre for the different antibody classes, most likely due to high inter-individual variability. However, we found a time-dependent increase in IgG-positive samples collected from day 41 up to day 206 post-PCR diagnosis. These data are in line with findings in human serum samples from a Chinese cohort showing persistence of IgG up to 6 months.31 To date, only a few studies have quantified virus-specific antibodies in prepandemic samples to establish cut-off values to discriminate between positive and negative samples,7 12 32 which allows comparison of results between studies. We found a similar proportion of positive samples for both IgA (from 72.9% in our study to 80.0%7 12 32) and IgM (72.9% in our study compared with 55.0% in the study reported by Peng et al13). Of the samples, 17.1% did not present virus-specific antibodies, which is in accordance with a previous study (Fox Iscience). Also, accumulating data report the lack of SARS-CoV-2 IgG in serum after previous infection in some individuals; in fact, in a cohort study (n=2547),13 6.3% were reported to be IgG seronegative.

In this study, we also assessed the presence of antibodies against other non-structural viral proteins, specifically the viral cysteine-like protease, also known as 3CLpro or main viral protease (MPro).18 Our data showed the presence of anti-MPro IgA and IgG antibodies in milk samples from the COVID-19 group compared with prepandemic samples, although the sensitivity was lower than when using the RBD antigen for detection of virus-specific antibodies. MPro is a viral antigen not exposed on the viral particle like the spike protein; however, strong and similar reactivities were found for both MPro and RBD, and the nucleocapsid protein in serum and saliva samples.32 Our study is the first to use MPro for detection of SARS-CoV-2 antibodies in breast milk, and the reactivities to the different viral antigens, also in function of isotype, have been previously reported in breast milk.7 34

Our results are in agreement with previous data showing higher levels of antibodies against SARS-CoV-2 in milk from infected/recovered mothers compared with samples from women before the pandemic.30 35 However, prepandemic samples showed some reactivity to SARS-CoV-2, particularly in RBD-reactive IgA, which may be explained by cross-reaction with other seasonal coronavirus (HCoV) in breast milk samples before 2020, as previously reported.68 Women with COVID-19 symptoms showed slightly higher virus-specific IgA levels in milk compared with women with asymptomatic infection, although differences were not significant. Moreover, no differences in IgM or IgG levels were found, possibly due to minor COVID-19 symptoms (pain, headache, etc) in this data set. Despite these observations, further analyses including a bigger sample size and different symptoms as well as severe COVID-19-infected donors are warranted.

In summary, our study demonstrates (1) the absence of SARS-CoV-2 RNA in breast milk from women with COVID-19 and (2) the high intervariability and intraviability in the SARS-CoV-2 antibody response. Women with COVID-19 exhibited IgA, IgG and IgM antibodies in breast milk not only against structural proteins like RBD but also against non-structural proteins like MPro. The presence of Igs suggests that breast milk might have a protective effect in newborns. Interestingly, positive associations between total IgA and specific antibodies (IgA, IgG and IgM) were observed, although their persistence and stability differed between mothers and antibody type. Our study endorses the safety of breast feeding during the pandemic and highlights the potential relevance of virus-specific SARS-CoV-2 antibodies providing passive immunity to breastfeeding infants, protecting them against COVID-19. Our study supports official recommendations stating the safety of breast feeding during the COVID-19 pandemic, indicating that breast feeding should be a priority with potential benefit for both mothers and neonates.

Author affiliations
1Department of Biotechnology, Institute of Agrochemistry and Food Technology-National Research Council (IATA-CSIC), Paterna, Valencia, Spain
2Department of Preservation and Food Safety Technologies, Institute of Agrochemistry and Food Technology-National Research Council (IATA-CSIC), Paterna, Valencia, Spain
3Department of Gynecology and Obstetrics, Hospital Universitario Dr Pset, Valencia, Spain
4Department of Paediatrics, Hospital Clínico Universitario de Valencia, Nutrition Research Group of INCLIVA, Valencia, Spain
5Health Research Institute La Fe, Neonatal Research Group and University Polytechnic Hospital La Fe, Division of Neonatology, Valencia, Spain
6Department of Endocrinology, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain
7Department of Infectious and Imported Diseases, Paediatric Unit, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain
8BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clinic, University of Barcelona, CIBERER, Barcelona, Spain

Correction notice  This paper has been corrected since it was published online. The Collaborators section was inadvertently omitted.

Twitter Walter Randazzo @walter_onair and Maria Carmen Collado @mcarmencollado

Acknowledgements  We thank all the families who were involved in the study during this difficult time and in the middle of the COVID-19 pandemic, as well as the collaborators of the MilkCORONA, which includes neonatologists, paediatricians, midwives, nurses, research scientists and computer/ laboratory technicians. This study represents a cooperative effort between different groups in Spain.

Collaborators  MilkCORONA Collaborators: Elena Crehuá-Gaudiz, Javier Estañ-Capell from Pediatric Nutrition Research Group of INCLIVA Biomedical Research Institute of Valencia and Department of Pediatrics, Hospital Clínico Universitario, University of Valencia, Spain. Asunción Obiol, Reyes Balanza, Department of Gynecology and Obstetrics, Hospital Universitario Clínico San Cecilio, Granada and BioHealth Research Institute (IBS), Granada, Spain. María José Rodríguez-Lagunas, Karla Río-Cantón, Miquel Recasens, Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu, Barcelona, Spain. Sara Ruiz, Marta Fabre, Hospital Clínico Universitario Lozano Blesa, Zaragoza. Instituto de Investigación Sanitaria Aragón (IIS Aragón). Federico García-García, Department of Microbiology, University Clinical Hospital San Cecilio, Granada and BioHealth Research Institute (IBS), Granada, Health Sciences Technological Park, Granada, Spain. Maria Rodríguez-Lagunas, Karla Río-Cantón, Joaquín Trasobares, Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain. José Luis Castresana, Departamento de Nutrición y Food Safety Research Institute (INSA-08921 Santa Coloma de Gramenet, Spain.

Contributors  Study concept and design: CM-C and MCC. Drafting of the manuscript: CB, WR, CM-C and MCC. Clinical aspects including recruitment of the participants, collection of samples and medical records: CM-C, LM, AP-L, EGV, CL, VF, FCrO, FCrI, GR, CC and GR-R. Sample management, processing and analysis: CB, WR, MS-R, GS, FIP-C and MCC. All authors read and approved the final manuscript.

Funding  This study has been supported by a research grant from Fundación La Marató-T3V (MilkCORONA, ref 202106).

Competing interests  None declared.

Patient consent for publication  Not required.

Ethics approval  All protocols performed in the study were in accordance with the ethical standards approved by the Ethical Committee of the Hospital Clínico Universitario de Valencia (ref 2020/133). A control group of women not exposed to SARS-CoV-2 and from pandemic time were included. These women were randomly selected from the MAMI birth cohort in Spain (ClinicalTrials.gov identifier: NCT03552939). This protocol was approved by the Ethical Committee of the Hospital Clínico Universitario de Valencia (ref 2015/0024) and by the local Ethical Committee of Atención Primaria-Generalitat Valenciana (CEIC-APCV).

Provenance and peer review  Not commissioned; externally peer reviewed.

Data availability statement  Data are available upon reasonable request. Data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material  This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminologies, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs  Gloria Sánchez http://orcid.org/0000-0001-7022-661X Cecilia Martínez-Costa http://orcid.org/0000-0003-1347-7521 María Carmen Collado http://orcid.org/0000-0002-6204-4864

REFERENCES
11. Forx A, Marino J, Amanat F. The spike-specific IgA in milk commonly-elicited after SARS-CoV-2 infection is concurrent with a robust secretory antibody response, exhibits neutralization potency strongly correlated with IgA binding, and is highly durable over time. *medRxiv*2021;03.16.21253731.


